Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action

World Journal of Biological Psychiatry

Volumn 10, Issue 2, 2009, Pages 117-126

  Kasper, Siegfried ^a   Hamon, Michel ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

5 HT2C receptors; Agomelatine; Major depressive disorder; Melatonergic receptors

Indexed keywords

AGOMELATINE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; SEROTONIN 2C RECEPTOR; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DOPAMINE; HYPNOTIC SEDATIVE AGENT; NORADRENALIN; SEROTONIN;

CHRONIC STRESS; DEPRESSION; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FORCED SWIMMING TEST; HUMAN; LEARNED HELPLESSNESS; NONHUMAN; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP WAKING CYCLE; TRANQUILIZING ACTIVITY; WEIGHT GAIN; WITHDRAWAL SYNDROME; ANIMAL; CIRCADIAN RHYTHM; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; MAJOR DEPRESSION; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ACETAMIDES; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; CIRCADIAN RHYTHM; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; HUMANS; HYPNOTICS AND SEDATIVES; NOREPINEPHRINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN;

EID: 67650120554     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970902717024     Document Type: Review

References (80)

1. Armstrong SM, Mac-Nulty OM, Guardiola-Lemaitre B, Redman JR. 1993. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 46:45-49
2. Audinot V, Mailliet F, Lahaye BC, Bonnaud A, Le Gall A, Amosse C, et al. 2003. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedeberg's Arch Pharmacol 16:553-561.
3. Baghai TC, Volz HP, Moller HJ. 2006. Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 7:198-222.
4. Barden N, Shink E, Labbe M, Vacher R, Rochford J, Mocaer E. 2005. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 29:908-916.
5. Bertaina-Anglade V, Drieu-La-Rochelle C, Boyer PA, Mocaer E. 2006. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 17:703-713.
6. Borjigin J, Li X, Snyder SH. 1999. The pineal gland and melatonin: molecular and pharmacologic regulation. Annu Rev Pharmacol Toxicol 39:53-65.
7. Bourin M, Mocaer E, Porsolt R. 2004. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 29:126-133.
8. Brown R, Kocsis JH, Caroff S, Amsterdam J, Winokur A, Stokes PE, et al. 1985. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. Am J Psychiatry 142:811-816.
9. Cajochen C, Krauchi K, Wirz-Justice A. 2003. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 15:432-437
10. Claustrat B, Chazot G, Brun J, Jordan D, Sassolas G. 1984. A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol Psychiatry 19:1215-1228.
11. den Boer JA, Bosker FJ, Meesters Y. 2006. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychophar-macol 21(Suppl 1):S21-S24.
12. El Yacoubi M, Coupe B, Gabriel C, Mocaer E, Costentin J, Vaugeois JM. 2006. Chronic agomelatine and fluoxetine treatments induce antidepressant effects in H/Rouen mice, a new genetic mouse model of depression. Eur Neuropsycho-pharmacol 16:S344.
13. Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, et al. 2001. 5-Hydroxytryptamine (5HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 21:8188-8197.
14. Grassi-Zucconi G, Semprevivo M, Mocaer E, Kristensson K, Bentivoglio M. 1996. Melatonin and its new agonist S-20098 restore synchronized sleep fragmented by experimental trypa-nosome infection in the rat. Brain Res Bull 39:63-68.
15. Griebel G, Simiand J, Serradeil-Le-Gal C, Wagnon J, Pascal M, Scatton B, et al. 2002a. Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99: 6370-6375.
16. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, et al. 2002b. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro- 4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR 125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333-345.
17. Hanoun N, Mocaer E, Boyer PA, Hamon M, Lanfumey L. 2004. Differential effects of the novel antidepressant agomelatine (S20098) versus fluoxetine on 5-HT(1A) receptors in the rat brain. Neuropharmacology 47:515-526.
18. Henn FA, Vollmayr B. 2004. Neurogenesis and depression: etiology or epiphenomenon? Biol Psychiatry 56:146-150.
19. Kasper S. 1993. Is severe depression a different illness? The pharmacological evidence. Eur Neuropsychopharmacol 3: 215-217.
20. Kasper S. 1995. Diagnosis and clinical course in mood disorders and depression subtypes. Depression 3:125-128.
21. Kasper S, Wehr TA. 1992. The role of sleep and wakefulness in the genesis of depression and mania. Encephale 18:45-50.
22. Kasper S, Sack DA, Wehr TA, Kick H, Voll G, Vieira A. 1988. Nocturnal TSH and prolactin secretion during sleep deprivation and prediction of antidepressant response in patients with major depression. Biol Psychiatry 24:631-641.
23. Kasper S, Lepine JP, Mendlewicz J, Montgomery SA, Rush AJ. 1994. Efficacy, safety and indications for tricyclic and newer antidepressants. Depression 2:127-137.
24. Kempermann G, Kronenberg G. 2003. Depressed new neurons-adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry 54:499-503.
25. Kennedy SH, Emsley R. 2006. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16:93-100.
26. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. 2008. A double-blind comparison of sexual functioning antideopressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 28(3):329-333.
27. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
28. Krishnan KRR. 2002. Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psychiatry 63(Suppl 1):25-29.
29. Kupfer DJ. 2006. Depression and associated steep disturbances: patient benefits with agomelatine. Eur Neuropsychopharmacol 16:S639-643.
30. Lam RW. 2006. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 21(Suppl 1): S25-29.
31. Lejeune F, Gobert A, Millan MJ. 2002. The selective neurokinin (NK)(1) antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study. Brain Res 935:134-139.
32. Lemoine P, Guilleminault C, Alvarez E. 2007. Improvement in subjective sleep in Major Depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 68:1723-1732. (Pubitemid 350247502)
33. Loo H, Hale A, D'haenen H. 2002. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-ht2c antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17:239-247.
34. Malberg JE, Schechter LE. 2005. Increasing hippocampal neurogenesis: A novel mechanism for antidepressant drugs. Current pharmaceutical design 11:145-155.
35. Manji HK, Gottesman II, Gould TD. 2003. Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Sci STKE 2003:pe49.
36. Mehtonen OP, Sogaard J, Roponen P, Behnke K. 2000. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry 61:95-100.
37. Millan MJ, Lejeune F, De Nanteuil G, Gobert A. 2001. Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J Neurochem 76:1949-1954.
38. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. 2003. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptami-ne(2C) receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306:954-964.
39. Millan MJ, Brocco M, Gobert A, Dekeyne A. 2005. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: Role of 5-HT(2C) receptor blockade. Psychopharmacology 177:1-12.
40. Mitchell PJ, Redfern PH. 2005. Animal models of depressive illness: the importance of chronic drug treatment. Curr Pharm Design 11:171-203.
41. Moller HJ. 2008. Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment. World J Biol Psychiatry 9:102-114.
42. Montgomery SA. 2006a. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol 16:S633-S638.
43. Montgomery SA. 2006b. Why do we need new and better antidepressants? Int Clin Psychopharmacol 21(Suppl 1): S1-10.
44. Montgomery SA, Kasper S. 2007. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 22:283-291.
45. Montgomery SA, Lecrubier Y. 1999. Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychophar-macology. Eur Neuropsychopharmacol 9:259-264.
46. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. 2004. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 19:271-280.
47. Murray CJ, Lopez AD. 1997. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436-1442.
48. Norman TR, Irons J, Cranston I. 2004. Effect of the novel antidepressant agomelatine in the olfactory bulbectomised rat. Int J Neuropsychopharmacol 7:02.
49. Ohayon MM, Shapiro CM. 2000. Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population. Compr Psychiatry 41: 469-478
50. Olie JP, Kasper S. 2007. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661-673.
51. Papp M, Gruca P, Boyer PA, Mocaer E. 2003. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28:694-703.
52. Papp M, Litwa E, Gruca P, Mocaer E. 2006. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 17:9-18.
53. Pitrosky B, Kirsch R, Malan A, Mocaer E, Pevet P. 1999. Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist. Am J Physiol 277:R812-R828. (Pubitemid 29458154)
54. Quera-Salva MA, Vanier B, Chapotot F, Guilleminault C, Vanier B, Chapotot F, et al. 2005. Effect of agomelatine on the sleep EEG in patients with major depressive disorder. Eur Neuropsychopharmacol 15(Suppl 3):S435-36.
55. Redman JR, Francis AJ. 1998. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J Biol Rhythms 13:39-51.
56. Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM. 1995. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berlin) 118:385-390.
57. Reul JM, Holsboer F. 2002. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2:23-33.
58. Reus VI, Wolkowitz OM. 2001. Antiglucocorticoid drugs in the treatment of depression. Expert Opin Invest Drugs 10: 1789-1796.
59. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44:77-87.
60. Sack RL, Lewy AJ, Hughes RJ. 1998. Use of melatonin for sleep and circadian rhythm disorders. Ann Med 30:115-121.
61. Souetre E, Salvati E, Belugou JL, Pringuey D, Candito M, Krebs B, et al. 1989. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 28:263-278.
62. Stahl SM, Entsuah R, Rudolph RL. 2002. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 52:1166-1174.
63. Thase ME. 2002. Comparing the methods used to compare antidepressants. Psychopharmacol Bull 36:1-17.
64. Thompson C, Franey C, Arendt J, Checkley SA. 1988. A comparison of melatonin secretion in depressed patients and normal subjects. Br J Psychiatry 152:260-265.
65. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. 2006. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9:519-525.
66. Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP, Smeraldi E, Rizzo F 2000. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 15: 29-34.
67. Van Reeth O, Olivares E, Zhang Y, Zee PC, Mocaer E, Defrance R, et al. 1997. Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters. Brain Res 762:185-194.
68. Van Reeth O, Olivares E, Turek FW, Granjon L, Mocaer E. 1998. Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist. Neuroreport 9:1901-1905.
69. Van Reeth O, Weibel L, Olivares E, Maccari S, Mocaer E, Turek FW. 2001. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am J Physiol Regul Integr Comp Physiol 280:R1582-1591.
70. Vida S, Looper K. 1999. Precision and comparability of adverse event rates of newer antidepressants. J Clin Psychopharmacol 19:416-426
71. Wehr TA, Wirz-Justice A. 1982. Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacop-sychiatria 15:31-39.
72. Weibel L, Turek FW, Mocaer E, Van Reeth O. 2000. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 880: 207-211.
73. Willner P, Muscat R, Papp M. 1992. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16:525-534.
74. Wilson S, Argyropoulos S. 2005. Antidepressants and sleep: a qualitative review of the literature. Drugs 65:927-947.
75. Winkler D, Pjrek E, Praschak-Rieder N, Willeit M, Pezawas L, Konstantinidis A, et al. 2005. Actigraphy in patients with seasonal affective disorder and healthy control subjects treated with light therapy. Biol Psychiatry 58:331-336.
76. Wirz-Justice A. 1995. Biological rythms in mood disorders. pp 999-1017.
77. Yous S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B, et al. 1992. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 35:1484-1486.
78. Zajecka JM. 2000. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 61(Suppl 2):20-25.
79. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, et al. 2000. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181.
80. Zupancic M, Guilleminault C. 2006. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 20:981-992.